Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPC Study Says New Drugs Offset Nondrug Spending: Will CBO Agree?

Executive Summary

A National Pharmaceutical Council-funded analysis of the value of newer medicines will give brand name pharmaceutical companies additional evidence to argue that the cost of a Medicare prescription drug benefit may be offset by savings in other health spending.

You may also be interested in...



FDA “Strategic Plan” Team Takes Shape: McClellan Names Senior Advisors

FDA Senior Economic Advisor Tomas Philipson, PhD, will work with Commissioner Mark McClellan, MD/PhD, to develop strategic initiatives

Milken Institute Center To Study FDA Approval Process, Innovation Strategies

The Milken Institute's Center for Accelerating Medical Solutions hopes to begin operations in Washington, D.C. during the summer

Milken Institute Center To Study FDA Approval Process, Innovation Strategies

The Milken Institute's Center for Accelerating Medical Solutions hopes to begin operations in Washington, D.C. during the summer

Related Content

UsernamePublicRestriction

Register

PS038546

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel